Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1998 Jun 15;187(12):1965–1975. doi: 10.1084/jem.187.12.1965

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Tethering of lymphocytes to purified PCLP under flow. (A) MECA-79 Western blotting of the purified PCLP, which was used in the flow chamber experiments, showing a major band at 160 kD. (B) Peripheral blood T lymphocytes or Jurkat T lymphoma cells were infused into the flow chamber at a constant wall shear stress, and the cell tethering rate to the PCLP-coated surface was determined. (C) Immobilized PCLP was treated with OSGE, sialidase, MECA-79, or PCLP mAb (3D3) before infusion of Jurkat cells. Jurkat cells were treated with L-selectin mAb (LAM1-3) or fucoidin before infusion. Error bars represent SD of measurements from at least three separate fields of view.

Tethering of lymphocytes to purified PCLP under flow. (A) MECA-79 Western blotting of the purified PCLP, which was used in the flow chamber experiments, showing a major band at 160 kD. (B) Peripheral blood T lymphocytes or Jurkat T lymphoma cells were infused into the flow chamber at a constant wall shear stress, and the cell tethering rate to the PCLP-coated surface was determined. (C) Immobilized PCLP was treated with OSGE, sialidase, MECA-79, or PCLP mAb (3D3) before infusion of Jurkat cells. Jurkat cells were treated with L-selectin mAb (LAM1-3) or fucoidin before infusion. Error bars represent SD of measurements from at least three separate fields of view.